Drug Profile
Somatropin oral - Emisphere Technologies
Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Emisphere Technologies
- Developer Emisphere Technologies; Novartis
- Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
- Mechanism of Action Human growth hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Growth disorders
Most Recent Events
- 08 Dec 2020 Emisphere Technologies has been acquired by Novo Nordisk
- 13 Aug 2011 Novartis terminates its licence for oral somatropin
- 13 Aug 2011 Discontinued - Phase-I for Growth disorders in USA (PO)